eMedicine Specialties > Rheumatology > Vasculitis

Takayasu Arteritis: Differential Diagnoses & Workup

Author: Mohammed Mubashir Ahmed, MD, Associate Professor, Department of Medicine, Division of Rheumatology, University of Toledo College of Medicine
Coauthor(s): Robert E Wolf, MD, PhD, Professor Emeritus, Department of Medicine, Louisiana State University Health Sciences Center at Shreveport; Chief, Rheumatology Section, Medical Service, Overton Brooks Veterans Administration Medical Center of Shreveport
Contributor Information and Disclosures

Updated: Feb 14, 2008

Differential Diagnoses

Aortic Coarctation
Kawasaki Disease
Atherosclerosis
Rheumatoid Arthritis
Behcet Disease
Sarcoidosis
Buerger Disease (Thromboangiitis Obliterans)
Systemic Lupus Erythematosus
Giant Cell Arteritis

Other Problems to Be Considered

Fibromuscular dysplasia
Spondyloarthropathies
Thromboembolism
Traumatic stenosis
Radiation fibrosis
Ergotism
Ehlers-Danlos syndrome
Marfan syndrome
Neurofibromatosis
Syphilis
Cogan syndrome

Workup

Laboratory Studies

  • The acute phase reactants and clinical parameters generally used to define active inflammatory disease do not universally reflect active blood vessel inflammation in Takayasu arteritis. The erythrocyte sedimentation rate is elevated in most but not all patients during active inflammatory disease. However, it is not a consistently reliable marker of disease activity, with both false-positive and false-negative associations being reported.
  • Other markers, including endothelin-1, von Willebrand factor, factor VIII antigen, and thrombomodulin, have been found to be inadequate markers of disease activity.

Imaging Studies

  • While imaging studies (CT scan, MRI) show typical patterns of stenoses or aneurysms of the arteries, angiography remains the criterion standard for diagnosis and evaluation of the extent of disease. However, recent studies suggest that noninvasive imaging modalities such as MRI, ultrasonography, and 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) allow diagnosis of Takayasu arteritis earlier in the disease course than standard angiography and provide a means for monitoring disease activity.
    • Angiography can evaluate only the appearance of the lumen and cannot differentiate between active and inactive lesions.
    • Takayasu arteritis can be divided into 6 types based on angiographic involvement.
      • Type I - Branches of the aortic arch
      • Type IIa - Ascending aorta, aortic arch, and its branches
      • Type IIb - Type IIa region plus thoracic descending aorta
      • Type III - Thoracic descending aorta, abdominal aorta, renal arteries, or a combination
      • Type IV - Abdominal aorta, renal arteries, or both
      • Type V - Entire aorta and its branches
  • Other tests
    • Magnetic resonance angiography (MRA) is equally or more sensitive than angiography for revealing lesions in the aorta and its brachycephalic branches but is less sensitive for helping detect smaller branch involvement. MRA that uses fast spin-echo sequences designed to enhance the detection of vessel wall edema has shown promise in assessing disease activity before irreversible lesions develop.
    • CT helical scanning angiography also has been shown to be sensitive and specific as a diagnostic tool.
    • Color Doppler ultrasonography provides details of the vascular wall, lumen, and flow and is a useful tool for screening and follow-up, particularly for carotid and subclavian arteries.
    • Positron emission tomography (PET) scanning with radioactive-labeled 18-fluorodeoxyglucose (FDG) has been shown to be useful in monitoring disease activity and response to treatment in preliminary studies. Presence or absence of FDG uptake correlates well with clinical state and MRI findings. Its use in patients with Takayasu arteritis requires further investigation.
    • MRA or CT angiography and FDG-PET may be useful to monitor vascular response to treatment.

Procedures

  • Biopsy of medium- to large-sized vessels may be diagnostic in early stages of the disease; however, in the chronic phase, diagnosis by biopsy alone is inadequate. In contrast to other vasculitides, tissue biopsies play little to no role in the diagnosis of Takayasu arteritis, as histologic examination of the great vessels is usually possible only at the time of vascular procedures or postmortem. Whenever possible, the feasibility of submitting some arterial tissue should be discussed with the attending surgeon prior to any surgical revascularization procedure.
  • Percutaneous balloon angioplasty can provide good outcomes for short lesions.
  • Conventional stents seem to be associated with high failure rate in patients with Takayasu arteritis.
  • Bypass graft surgery is the procedure with the best long-term patency rate.

Histologic Findings

Takayasu arteritis is characterized by a special pattern of histopathological changes. The early stage consists of a continuous or patchy granulomatous inflammatory reaction involving macrophages, lymphocytes, and multinucleated giant cells. Inflammation initially occurs in the vasa vasorum, with the artery wall becoming irregularly thickened and the lumen becoming narrowed. Takayasu arteritis progresses to a sclerotic stage, with intimal and adventitial fibrosis and scarring of the media.

More on Takayasu Arteritis

Overview: Takayasu Arteritis
Differential Diagnoses & Workup: Takayasu Arteritis
Treatment & Medication: Takayasu Arteritis
Follow-up: Takayasu Arteritis
Multimedia: Takayasu Arteritis
References

References

  1. Yagi K, Kobayashi J, Yasue S, et al. Four unrelated cases with Takayasu arteritis and CD36 deficiency: possible link between these disorders. J Intern Med. Jun 2004;255(6):688-9. [Medline].

  2. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. Jul 2004;50(7):2296-304. [Medline].

  3. Andrews J, Al-Nahhas A, Pennell DJ, Hossain MS, Davies KA, Haskard DO. Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann Rheum Dis. Aug 2004;63(8):995-1000. [Medline].

  4. Andrews J, Mason JC. Takayasu's arteritis--recent advances in imaging offer promise. Rheumatology (Oxford). Jan 2007;46(1):6-15. [Medline].

  5. Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of threecases. Ann Intern Med. Mar 2 1999;130(5):422-6. [Medline].

  6. Joh JH, Kim DK, Park KH, Kim DI. Surgical management of Takayasu's arteritis. J Korean Med Sci. Feb 2006;21(1):20-4. [Medline].

  7. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. Jan 2005;17(1):16-24. [Medline].

  8. Lie JT. Pathology of isolated nonclassical and catastrophic manifestations of Takayasu arteritis. Int J Cardiol. Oct 1 1998;66 Suppl 1:S11-21. [Medline].

  9. Numano F. Takayasu arteritis, Buerger disease and inflammatory abdominal aortic aneurysms: is there a common pathway in their pathogenesis?. Int J Cardiol. Oct 1 1998;66 Suppl 1:S5-10. [Medline].

  10. Numano F, Kobayashi Y. Takayasu arteritis--beyond pulselessness. Intern Med. Mar 1999;38(3):226-32. [Medline].

  11. Rizzi R, Bruno S, Stellacci C, Dammacco R. Takayasu's arteritis: a cell-mediated large-vessel vasculitis. Int J Clin Lab Res. 1999;29(1):8-13. [Medline].

  12. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol. Jan 2005;17(1):9-15. [Medline].

  13. Seo P, Stone JH. Large-vessel vasculitis. Arthritis Rheum. Feb 15 2004;51(1):128-39. [Medline].

  14. Sharma BK, Jain S, Sagar S. Systemic manifestations of Takayasu arteritis: the expanding spectrum. Int J Cardiol. Aug 1996;54 Suppl:S149-54. [Medline].

  15. Tanaka F, Kawakami A, Iwanaga N, Tamai M, Izumi Y, Aratake K. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med. 2006;45(5):313-6. [Medline].

  16. Yasuda K. Surgical treatment of Takayasu's Arteritis. Intern Med. Nov 1998;37(11):903-4. [Medline].

Further Reading

Keywords

Takayasu arteritis, TA, pulseless disease, Takayasu's disease, Takayasu's arteritis, Takayasu disease, aortic arch syndrome, middle aortic syndrome stenotic lesions, angioplasty, renovascular stenosis, coronary artery stenosis, extremity claudication, cerebral ischemia, critical stenosis, aortic regurgitation, thoracic aneurysm, abdominal aneurysm, percutaneous transluminal coronary angioplasty, PTCA

Contributor Information and Disclosures

Author

Mohammed Mubashir Ahmed, MD, Associate Professor, Department of Medicine, Division of Rheumatology, University of Toledo College of Medicine
Mohammed Mubashir Ahmed, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, and American Federation for Medical Research
Disclosure: Nothing to disclose.

Coauthor(s)

Robert E Wolf, MD, PhD, Professor Emeritus, Department of Medicine, Louisiana State University Health Sciences Center at Shreveport; Chief, Rheumatology Section, Medical Service, Overton Brooks Veterans Administration Medical Center of Shreveport
Robert E Wolf, MD, PhD is a member of the following medical societies: American College of Rheumatology, Arthritis Foundation, and Society for Leukocyte Biology
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Elliot Goldberg, MD, Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Temple University School of Medicine
Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, and American College of Rheumatology
Disclosure: Nothing to disclose.

CME Editor

Alex J Mechaber, MD, FACP, Assistant Dean for Medical Curriculum, Associate Professor of Medicine, Division of General Internal Medicine, University of Miami Miller School of Medicine
Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine
Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD, Professor of Medicine, Temple University School of Medicine; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital
Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, and Phi Beta Kappa
Disclosure: medifocus Honoraria Review panel membership; health dialogs Honoraria Consulting; Merck, Amgen, Biogen, Zimmer, Wyeth, Johnson&Johnson, Stryker, Medtronic, Zimmer.Abbott,  Ownership interest Other; West Penn Allegheny Health System Consulting fee Consulting; Alpharma Honoraria Consulting; Proctor&Gamble Grant/research funds Independent contractor

RELATED MEDSCAPE ARTICLES
Articles
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.